HER2 / ErbB2 / CD340 Antibody (Biotin), Mouse MAb

Catalog Number: **10004-MM01-B**

General Information	
Immunogen:	Recombinant Human ErbB2 protein (Catalog#10004-H08H)
Clone ID:	8B5D4C1
Ig Type:	Mouse IgG2a
Applications:	ELISA
Specificity:	Human ErbB2 / HER2 / CD340
Formulation:	0.2 μm filtered solution in PBS
Storage:	＜ -20℃

Preparation

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human ErbB2 / HER2 extracellular domain (rhErbB2; Catalog#10004-H08H; NP_004439.2; Met 1-Thr 652). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography and then biotinylated.

Applications

ELISA – This antibody can be used at 0.5-1 μg/mL as a detection antibody to detect Human ErbB2 in ELISA.

Specificity

Human ErbB2 / HER2 / CD340
No cross-reactivity in ELISA with
Human ErbB1 / EGFR
Human ErbB3 / HER3
Human ErbB4 / HER4
Human cell lysate (293 cell line)

Storage

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. **Preservative-Free.**
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. **Avoid repeated freeze-thaw cycles.**

Background

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.

Reference

Krawczyk N, *et al.* (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.